BOSTON — The SEC on Wednesday charged Gregory Lemelson and Lemelson Capital Management with fraudulently making $1.3 million by driving down the price of nonparty Ligand Pharmaceuticals in a “short-and-distort” scheme.
Categories / Securities
Subscribe to our free newsletters
Our weekly newsletter Closing Arguments offers the latest about ongoing trials, major litigation and rulings in courthouses around the U.S. and the world, while the monthly Under the Lights dishes the legal dirt from Hollywood, sports, Big Tech and the arts.
Additional Reads
-
-
Contempt for Musk clouds jury selection in Twitter takeover trial February 19, 2026
-
Ups and downs for Boeing investors February 18, 2026 -
